Blueprint Medicines Corp (NASDAQ:BPMC)
| 86.28 Delayed Data As of Jun 14 |  -0.61 / -0.70%Today’s Change | 66.20 Today|||52-Week Range 125.61 | -23.07% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $5.1B |
Company Description
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Contact Information
Blueprint Medicines Corp. 45 Sidney Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Mutual fund holders | 59.27% |
| Other institutional | 42.27% |
| Individual stakeholders | 10.15% |
Top Executives
| Jeffrey W. Albers | President, Chief Executive Officer & Director |
| Kathryn Haviland | Chief Operating Officer |
| Michael Landsittel | Chief Financial Officer |
| Becker Hewes | Chief Medical Officer |
| Fouad Namouni | President-Research & Development |
